TNFAIP8 promotes prostate cancer cell survival by inducing autophagy

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Designing the forward and reverse primers to analyze the expression of TNFAIP8 isoforms. (A) A schematic of the forward and reverse primer design process. (B) RT-PCR of total RNA from human monocytic leukemia THP-1 cells and human neuroblastoma SH-SY5Y cells. RNA of the five isoforms was amplified, and PCR products were electrophoresed on a 1.5% agarose gel stained with ethidium bromide. NC–negative control (no cDNA).



Supplementary Figure 2: The effect of TNFAIP8 expression on cell cycle progression. PC3 and LNCaP cells were transfected with empty vector or TNFAIP8-Myc plasmid for 30 h. Cells were stained with propidium iodide, and cell-cycle progression was monitored using flow cytometry. The percentages of cells in the G1, G2, and S phases were measured.



Supplementary Figure 3: TNFAIP8 expression is associated with LC3 β I/II expression in normal and breast cancer cells. (A) MCF7, MCF7-RAS, MCF7-ADR, MCF10A, MCF10A-Neo, MCF10A-RAS, MCF-10A-TGF α cells were grown for 30 h and cell lysates were immunoblotted with anti-TNFAIP8, anti-LC3 β I/II, anti-Beclin1, and anti-GAPDH antibodies. (B) MCF7 cells were transfected with empty vector or TNFAIP8-Myc plasmid. After 18 h, the medium was changed to serum-free (SF) medium or complete medium for an additional 24 h and 48 h. Cell extracts (40 µg) were immunoblotted with anti-LC3 β I/II, anti-LC3 β I/II, and anti-GAPDH antibodies as indicated.

Supplementary Table 1: The following primer sets were used for RT/qPCR analysis of TNFAIP8 and cell cycle-related gene expression

TNFAIP8 FP: 5'- CTTTGACCGGAATGTGTTATCCA -3' TNFAIP8 RP: 5'- CAAGGCAGCCAAAAATTCACAA -3'
CDK2 FP: 5'- CCAGGAGTTACTTCTATGCCTGA -3' CDK2 RP: 5'- TTCATCCAGGGGAGGTACAAC -3'
CDC20 FP: 5'- GCACAGTTCGCGTTCGAGA -3' CDC20 RP: 5'- CTGGATTTGCCAGGAGTTCGG -3'
MAD2L1 FP: 5'-GGACTCACCTTGCTTGTAACTAC -3' MAD2L1 RP: 5'-GATCACTGAACGGATTTCATCCT -3'
CDT1 FP: 5'- CGGTGGACGAGGTTTCCAG -3' CDT1 RP: 5'-CTGCCGGGGTGGATTTCTT -3'
PCNA FP: 5'- ACACTAAGGGCCGAAGATAACG -3' PCNA RP: 5'- ACAGCATCTCCAATATGGCTGA -3'
CHEK1 FP: 5'- ATATGAAGCGTGCCGTAGACT -3' CHEK1 RP: 5'- TGCCTATGTCTGGCTCTATTCTG -3'
CCNE2 FP: 5'- TCAAGACGAAGTAGCCGTTTAC -3' CCNE2 RP: 5'- TGACATCCTGGGTAGTTTTCCTC -3'
CCNB2 FP: 5'-TGCTCTGCAAAATCGAGGACA -3' CCNB2 FP: 5'-GCCAATCCACTAGGATGGCA -3'
CCNA2 FP: 5'- CGCTGGCGGTACTGAAGTC -3' CCNA2 RP: 5'- GAGGAACGGTGACATGCTCAT -3'
CDCA4 FP: 5'- GAGATGACGCAGGATGGGAC -3' CDCA4 RP: 5'- TCCACGTCTGAGAACAGCTCT -3'
CDC45 FP: 5'- GCACAGTTCGCGTTCGAGA -3' CDC45 RP: 5'- CTGGATTTGCCAGGAGTTCGG -3'
GAPDH FP: 5'- CCACCCAGAAGACTGTGGAT -3' GAPDH RP: 5'- GTTGAAGTCAGAGGAGACCACC -3'